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GROUP FOR RECOMBINANT TISSUE-TYPE PLASMINOGEN ACTIVATOR 
A new European Cooperative Study Group trial of 721 
patients has recently found recombinant tissue-type PIPS- 
mbqen activator @t-PA) to positively affect infarct size, 
kft ventrkular function, cardttvasculsr morbidity and 
early survivat. In this 26 center trbd, patients were ran-  
domized to receive either placebo or  100 mg r&PA intrave- 
nously over 3 h. Hepartn (5,000 U bolus injection and then 
1,OOtl U/h) and aspirin (250 mg initially, then 75 to 125 mg 
every other day) were given to ail patknts until angiogra- 
pby was performed (10 to 22 days after allocation). 
Enzymatic infarct size was found to be 20% smalkr in 
tbe t-t-PA gmup (2p = 0.0018) than in the control group. At 
angiography, 83% of r&PA-treated patients had a patent 
infarct-related vessel compared with 77% of the placebo. 
treated patknts. EJection fraction was 2.2% points higher 
.  .  
t6 ml smalkr (2p = 0.003) than in the control group, 
indicating an improved lett ventricutar pump function in 
tbe thrombolysts group. C~rdiivascular comptiitions such 
as shock, ventrkutar tibrittation and perkarditis were 
markedly fewer in patients treated with r&PA, but bkeding 
complications occurred more frequently. An intracranial 
hemorrhage withm 3 days after the infusion of t-t-PA was 
observed in g:e pat%& (1.4%). None of these bkeding 
episodes was causalty related to death. Although this Eu. 
ropean Cooperative trial was not designed prbnartly as a 
mortality study, important reductions in early mortatity 
size, preserve left ventricular function and, most important, 
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improve survival (I-16). The Gruppo Italian0 per lo Studio 
della Streptochinasi neli’lnfarto Miocardico (GISSI) trial (I), 
a randomized, controlled study of nearly 12,000 patients, 
was the first to show Improved in-hospital survival after 
intravenous infusion of a thrombolytic agent (streptokinase), 
particularly when administered within the first 3 h after the 
onset of symptoms. The improved survival after intravenous 
streptokinase has been confirmed recently in an even larger 
multicenter study, the Second International Study of infarct 
Survival (ISIS-2) trial (8). which reported a significant reduc- 
tion in 5 week vascular mortality. Improved early survival 
01988 by the Amencan College al Cardiology 0735.1097/8863.50 
was also demonstrated for a \treptokma\e-derived throm- Tahlc I. B<~\elme Characten\tlc\ of 721 Pat~enr\ 
bolytic agent, amsoylated pla\mmogen \trep!okina\e actlva- Pl.,ceho n-p,\ 
tor complex (APSAC) (9). and very recently al\o for recom- I ”  = Ml in : “ :  
binant tissue-type plasminogen activator (rt-PA) (16). -  
The mechanism responsible for these beneficia! ~+&I\ I\ 
a& cyr, 5x I41 I,, h9, vi IJI I” 6’9) 
MN II!4 IRll 111 w 
most probably related to coronary artery recanalirittlon with Hi\lor) of prvv,oa\ mf.~rctwn ?hl7 I I  27 17 hl 
salvage of ischcmic mvocardium. in thi\ rejoect. rl-PA. a i\nterlor mf‘!ritlnn I?‘) II0 IJ5 IJII 
more physiologic and librin+pec;fic agent. has been shown 
to have greater thrombolytic efficacy than \treplokina\e (17-  
19). Indeed, combining the results of two multlcenter trlale 
the European Cooperative Study Group trial !19) and the 
Thrombolysis in Myocardial Infarction (TIMI) phase I trial 
(18)-the patency rate of the infarct-related vessel wa\ 
significantly greater with &PA than with \treptokmd\e. 
irrespective of whether treatment wa\ apphed in the first 3 h 
or  at 3 to 6 h (17). The European Cooperative Study Group 
has recently conducted a large pro\pectlve placebo-con- 
trolled trial to study the effect of intravenou\ rr-PA on 
enzvmatic infarct size. left ventricular function and climcal 
follow-up (20). A full list of collaborating hospital\ and 
assessment groups is given in the mam report (IO). The mo\t 
striking results of this study and the insights we have gained 
are presented here. 
and 96 h after the start of the ewoerimental infusion for local 
a\\e\\ment of cardiac enzyme; and for central analysis of 
dlpha-hydrouybutyrate dehydrogenase (HBDH) activities in 
plasma. The cumulative myocardial release of HBDH into 
plasma wa\ determined centrally as previously described 
(21.22). The value at 72 h wa\ used as an estimate of infarct 
Methods 
we. 
No prerrc~cruncn~ ungiopruphy WIS prrfurnwl. Between 
!Mection of patients. The entry criteria of the trial in- IO to 22 days after allocation. coronary arteriography and 
eluded: age 171 years; chest pain typical of myocardial left ventricular angiography were performed and recorded 
ischemia for ~30 min and <5 h unrelieved by nitroglycerin; on 35 mm film. All films were centrally analyzed by the 
ST segment elevation 22 mm in two or  more electrocardio- Angiography Assessment Group. Patency of the infarct- 
graphic (ECG) limb leads or  leads Vs and V,. ~3 mm in at related verse1 was assessed according IO the TIM1 criteria 
least two precordial leads or  21 mm in two limb leads or  (18). Left ventricular volumes and ejection fraction were 
leads V, and V, together with 22 mm of ST segment 
depression in two or  more precordial leads. Exclusion 
criteria were previous myocardial infarction at the same site 
or  previous coronary artery bypass surgery, previous myo- 
cardial infarction at any site durin: the preceding 2 weeks 
and contraindications for thrombolytic therapy. 
Protoed. Every patient was given 250 mg of aspirin 
intravenously followed by 75 to 125 mg of oral aspirin every 
other day and 5,000 IJ of heparin administered as a bolus 
followed by 1,000 U/h. The patients were then randomized 
by a telephone answering service and allocnted to either 100 
mg single-chain II-PA or  placebo. The total individual dose 
of 100 mg powdered &PA was dissolved in 100 ml solvent 
and the undiluted product was administered (IO mg as a 
bolus followed by 50 mg over I h  and 40 mg over the next 2 
h). In patients allocated to conventional treatment, placebo 
was given in exactly the same way as &PA. After 3 days 
heparin could be replaced by oral anticoagulants. Any other 
treatment was given only if clinically indicated. At dis- 
charge, a beta-adrenergic blocker was given to both groups 
unless contraindicated. 
Blood samples were drawn before and at I2.24,36,48.72 
measured from the 30”  right anterior oblique projection using 
the area-length method. 
Results 
Patient characteristics (Table I). A total of 721 patients 
entered the trial in 26 participating hospitals. Of these 
patient\. 366 were allocated to placebo and 355 to II-PA. in 
eight patients the experimental infusion was not given be-  
cause of protocol violation in three patients and various 
clinical reasons in five patients. These eight patients were 
included in the analysis according to their treatment alloca- 
tion (“intention to treat” principle). 
Boseline churcrcteristic.s on crdnission were .sbnilur in llrr 
IWO mwmrenf groups (T&/e I). The delay between the onset 
of symptoms and the start of the experimental infusion was 
2.8 h (90% range I.3 to 4.5) in the placebo group and 2.9 h 
(90% range 1.4 to 4.6) in the rt-PA group. 
Clinical Uluw-up (Table 2). The administration of rt-PA 
was associated with an improved short-term survival. Com- 
pared with the placebo group, the reduction in mortality rate 
in patients treated with rt-PA was from 5.7% to 2.8% at I4 
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Table 2. Clinaxl Follow-Up 
Placebo 
frt=366) 
n-PA 
1”  = 355)  Rate Ratio 
95% 
Confidence 
Interval 
Moriahty at 14 dayr 
Total group 
Treated C3 h or  symPt”ms onset’ 
Bleedmg comphcatlons and stroke 
Documented hemorrhagic stroke 
Documented nonhemorrhagic stroke 
Nondocumented stroke 
Gastromtesrmat bleeding 
Macroscup~c hemalaria 
Local hemamma 
Other bleeding 
Blood transfusion gave” 
Cardiac comphcatmns during hospital slay 
Rel”faKtl”” 
Shock 
Pulmonary edema 
Pencarditir 
Ventricular librdlarion 
3rd" AV block 
Supraventricular tachyarrhythmia 
Angioplasly 
CABG 
Angioplarly and CABG 
Status at 3 months 
MGnahly 
Total group 
Treated <3 h or  symptoms o”sel* 
Reinfarclion 
Ang~oplasty 
CABG 
Angoplasty and CABG 
21 (5.7) 
I3 16.3) 
2117.4) 
2 (0.6) 
4 (1.1) 
4t1.11 
9t2.51 
I5 (4.1) 
7Cl.9) 
I5 (4.1) 
22 (6.0) 
24 (6.6) 
4Ofll) 
23 (6.3) 
I8 (5.0) 
38 (10.4) 
9 (2.5) 
I (0.3) 
I (0.3) 
29 (7.9) 
I7 (8.2) 
23 (6.2) 
I6 (4.4) 
I7 (4.6) 
2 (0.5) 
IO (2.8) 0.49 
2 (I.11 0.18 
I04 (29.3) 3.97 
6 (1.7) 
I (0.3) 
5 11.4) 
16 (4.5) 
68 (19)  
30 (8.5) 
I3 (3.7) 1.92 
I4 (3.9) 
9f2.5) 0.37 
22 (6.3) 
22 (6.3) 0.57 
12 (3.4) 0.54 
II (3.1) 0.63 
27 (7.6) 0.73 
90.5) 
IO (2.8) 10.3 
I (0.3) 
I8 (5.1) 0.64 
6 (3.4) 0.41 
21 (5.9) 0.94 
22 (6.2) I .42 
32 (9.0) I .94 
2 (0.6) 1.03 
0.24 10 I.01 
0.05 lo 0.69 
2.6910 5.91 
0.80 to 4.62 
0.17 to 0.83 
0.35 ID 0.93 
0.28 to 1.05 
0.31 to 1.29 
0.46,~~ I.17 
I .72 to 62.0 
0.36 to I.13 
0. I7 to 0.98 
0.53 IO 1.66 
0.77 to 2.61 
I.11 IO 3.41 
0.18 to 5.82 
‘207 patients alloca!ed to placebo. 179 patients allocated lo n-PA. The actual “amber of palienls with an event 
is given: percan! of patients in each ireatment group is show” in parenlheses. Rate ratio and 95% confidence interval 
are pven when appropriate. CABG = coronary a2tery bypass grafting. 
days (a 51% reduction, 95% confidence interval -76% to 
+ 1%. 2p = 0.053) and from 7.9% to 5.1% (a 36% reduction, 
95% confidence inten~al -63% to +13%, 2p = 0.121) at the 
3 month follow-up. In patients treated within 3 h of the onset 
of symptoms, the reduction in mortality rate was 82% (95% 
confidence interval -95% to -31%. 2p = 0.009) at 14 days 
(from 6.3% in the placebo-treated group to I. 1% in the group 
receiving rt-PA) and 59% (95% confidence interval -83% to 
-2%. 2p = 0.045) at 3 months (from 6.2% to 3.4%). 
Cardiovascular complications daring the hospital slay 
were less frequent in patients ireated with rt-PA. For exam- 
ple, a 63% reduction in the incidence of cardiogenic shock 
and a 40 to 50% reduction in the incidence of ventricular 
fibrillation and pericarditis were observed. Angioplasty was 
performed in a similarly low percent of patients in both 
groups (2.5%). Coronary bypass surgery was performed in 
IO rt-PA-treated patients and in only one control patient. 
Bleeding complications were more frequent in patients 
treated with r&PA. Intracranial bleeding was observed in six 
patients allocated to rt-PA. In one of these six patients 
neurologic symptoms and death occurred on the 15th day, I2 
h after treatment with angioplasty and intravenous strepto- 
kinase for reocclusion. In the remaining five patients (I .4% 
of the r&PA-treated patients), the neurologic symptoms 
occurred within 3 days after the infusion of rt-PA. In none of 
these five patients was the bleeding causally related to death. 
One patient died of cardiogenic shock and ventricular Iibril- 
lation due to reinfarction a few hours after the interruption of 
the heparin infusion. Gastrointestinal and other major bleed- 
ing episodes were relatively infrequent. Blood transfusions 
were required in 3.7% of the rt-P&4-treated patients. 
After 3 months the incidence of reinfarction was very 
similar in both groups. Angioplasty or coronary artery 
bypass surgery, or both, was performed in a greater propor- 
tion of patients allocated to rt-PA-(15.8% versus 9.6%, 
respectively). 
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Table 3. Enzymcuc Infarct Sire and Left Ventricular Funcuon 
Pl.,cehn n-PA 
HBDH-Q72’ Xh7 Il?l-!I471 h’J7 ,  I  I’J-IYX’JI 
W/liter) In = iI41 I ”  = 7051 
smaller m pauents allocated tort-PA than in control patients 
All these drfferences were slatistically \igniqcant. 
Discussion 
FJKIIOII fraction+ JX5lrll 3, $0 7 I  + IO  9, 
I%) in = ?HX) I ”  = 2x91 EtTect on ir&arrt sire and ventricular function. The Euro- 
Left venttudw volumes (ml) pean Cooperative rt-PA versus placebo trial (20)  I\ the first 
End-draPtolict I?J?i!lJhl IIX!I+IF!1 trral to rhow d beneficial effect cf intravencus thrombolytic 
End-sysrnlict 656ir?Y71 5YXI?!X I, 
(II = 2x71 I” -  2x21 
therapy on Infarct size, left ventricular function. cardiovas- 
cular morbidity and mortality within the same study popu- 
*2p = 0 WI% :?p = LJ 04. $1~ = lJ.lJiJ3 Data ,a @“en I I \  mr ! . .m  01 mwn Jatron. The intravenous administration of r&PA within 5 h of 
values: !?O% ranges or standard devlatlonc dre \houn in pxentle\e\ H B D H -  
Q72 = EUIIIU~~IIW release O f  alpha-hydroxyhutj tdle dehydrogna\e IO IO  
onset of an acute myocardial infarction significantly reduced 
plasma up IO  72 h. r & P A  = recombwant hrsue-typr plr\mmogcn ~twdlor 
mfarct \ize ty 20%. A reduction in infarct srze measured by 
enzymatic methods was also demonstrated for intravenous 
\trep:okinace in the Intravenous Streptokinase in Acute 
k4yocardral Infarction (ISAM.) trial (2). The reduction in 
Infarct size and angingraphie findings (Table 3, Fig. I). enzymatic infarct size in the European trial was acsociatcd 
The cumulative myocardial re!ease of HBDH into plasma up with a nre\erved left ventricular function. Global ejection 
to 72 h was 28% higher in the control group than in pauents fraction’ was 2.2 perctntage points higher in patients ai!@ 
treated with &PA; 867 U/liter (90% range 123 to 2.143) cated to rt-PA than in the alacebo moue. As in two other r  -  
versus 697 1Jlliter (90% range t 19 to 1 X89). These results studies wrth streptokinase (5.23). end-diastolic and end- 
indicate a significant reduction in infarct size in the throm- systolic volumes were significantly smaller in patients allo- 
bolysis group (2p = 0.0018). cated to r&PA. These findings suggest that early reperfusion 
Angiography could not be performed in 22 patients (6.2%) not only improves contractile function but also prevents or  
allocated to thrombolysis and in 30 patients (8.2%) allocated at least hmits infarct expansion and cardiac dilation. The 
to conventional treatment, including the patients who died latter effect might be of great clinical importance because rt 
before catheterization. 1 he infarct-related coronary artery has been shown that ventricular volumes may have a greater 
could not be identified in 26 rt-PA-treated and in I I placebo- predictive value for late survival after infarction than does 
treated patients in whom angiography was performed. A the ejection fraction (24). However. it seems unlikely that 
high percent of patent (TIM1 grades 2 and 3)  coronary this improvement. albeit moderate, in left ventricular pump 
arteries was found in both groups IO to 22 days after the functron is the sole mechanism responsible for the major 
experimental treatment: 77% in the placebo group and 83% clinical benefit observed in the trial. 
in the &PA group (Fig. 1). In 80% of the recruited patients Infarct-relafed arterial patency rates. The patency rates 
(n = 577) the left ventricular angiogram was adequate for (TIM1 grades 2 and 3)  of the infarct-related vessel at IO IO 22 
quantitative analysis. Global ejection fraction was 2.2 per-  days after admission were remarkably high: 83% in the II-PA 
centage points higher and left ventricular volumes 26 ml group and 77% in the control group. This late patency rare of 
77% in the control group is higher than those reported by 
Rentrop et al. (25)  at IO to I4 days (67%) and White et al. (5)  
Figure 1. Patency (according to Thrombolysrs in Myocardial Infarc- 
lion [TIM!] criteria) of the infarct-related coronary artery. IO to 22 
days after allocation. The number of patients in the different 
subgroups are shown next to the bars. &PA = recombmant 
tissue-type plasminogen activator. 
at 3 weeks (54%) in patients not receiving thrombolytic 
treatment. It can be assumed that the very early inlravenous 
administration of aspirin and heparin. followed by oral 
aspirin and continuous anticoagulation. in the European 
Cooperative study was beneficial by enhancing both endog- 
enous and rt-PA-induced thrombolysis and also by prevent- 
ing rethrombosis of the infarct-related vessel. 
Mortality. Although not designed primarily as a mortality 
study. the trial demonstrated that the administration of rt-P.4 
for acute myocardial infarction is associated with an im- 
proved short-term survival. Despite very low mortality rates 
in the control group. a reduction in mortality rate at 14 days 
of 51% was observed in the total group of parients allocated 
to &PA :from 5.7% to 2.8%). In patients in whom the r&PA 
infusion was started within 3 h of onset of symptoms, the 
reduction m mortality rate at 14 days was 82% (from 6.3% to 
IBA “ A N  D E  WERP ET AL 
~UROI’kAN C O O P f . R A T I V f :  HT.PA V S  PLACf’BO TRIAL 
at 2ld at 21d at 35d at l&d at 30d at 30d 
Or?,‘3 “.17‘, “.7‘6, 1-368 “:,OO‘ 0=5103 
1 ,’ n “I. ,,,,: % .
1.1%). At 3 month follow-up the reductions in mortality rate 
were 36% for the total group (from 7.9% to 5.1%) and 59% 
for patients treated within 3 h (from 8.2% to 3.4%). These 
mortality rates are nearly identical to those recently reported 
by the European Cooperative Study Group for a similarly 
selected and treated group of patients (26) and are the lowest 
published so far in large thrombolysis trials. 
Mortality rates in the placebo group were very low when 
compared with those in other studies of intravenous throm- 
bolyuc therapy (I-$. 2). 11 is unlikely that this is caused by 
selection of a low risk group of patients because the ECG 
criteria were more stringent than in the other studies and 
because oatients with cardioaenic shock or previous infarc- 
tion were not excluded. In v&w of the recent findings of the 
ISIS-2 trial it is verv likelv that the administration of low dose 
aspirin and heparin in the European Cooperative trial may 
have contributed not only to the high patency rates of the 
infarct-related vessel (previously mentioned) but also to the 
lower mortality rates when compared with the Anglo- 
Scandinavian Study of Early Thrombolysis (ASSET) trial 
(16). The 51% reduction in mortality rate found in the Euro- 
pcan Cooperative trial despite a very low mortality rate in the 
placebo group undoubtedly supports the efficacy of n-PA. 
Complications. In addition to the mortality reduction, the 
incidence of cardiovascular complications (e.g., shock. peri- 
carditis, ventriculz ftbrillation) was markedly lower in the 
thrombolysis group. On the other hand, bleeding complications 
occurred more frequently in r&PA-treated patients. The inci- 
dence of intracranial bleeding after rt-PA of 1.4% (5 of 355 
patients) in this trial contrasts with the 0.3% incidence (only I 
OT 367 patients) in the other recently reported trial from the 
European Cooperative Study Group (26) in which entry crite- 
ria, treatment regimens with rt-PA. heparin and aspirin were 
at l&d 
n=721 
, A C C  Vo, I I .  No ‘I 
Dcccmher 19WX 14A-YA 
Figure 2. Early mortaliry rales in large 
pktcebo-controlled trial\ wilh inlrave- 
nously administered thromholytic 
agenlc The time window for trealmenl 
and the percent mortalny reduction ob- 
served in each trial are shown at the 
top of the bars. The number of palients 
allocated within the given lime window 
are shown below. The third bar on the 
right side indicates the I4 day mortality 
rate in Is4 rt-PA-treated patients from 
the previously reported European trial 
(ref. 261. AIMS = AIMS trial (ref. 9): 
APSAC = anisoylated plasminogen 
streptokinase activator complex; 
ASSET = ASSET trial (ref. 16): Eur 
rt-PA = European Cooperative trials 
with n-PA (present study and ref. 26): 
GISSI = GISSI trial (ref. 1): ISAM = 
ISAM trial (ref. 2): ISIS-2 = ISIS-2 
trial (ret 8): SK = streptokinase: II-PA 
= recombinant tissue-type plasmino- 
gen activator; WW = Western Wash- 
ington trial (ref. 4). 
identical. When the data of these two European trials are 
combined. the total incidence of intracranial hemorrhage was 
0.8% (6 of 722 patients). Among 3,768 patients treated with 80 
to 120 mg rt-PA from Genentech Inc. and Boehringer Ingel- 
heim CmbH up to the summer of 1987, an intracranial bleeding 
episode occurred in 0.4% (95% confidence interval 0.2% to 
0.6%) of the patients (27). The number of gastrointestinal or 
other major bleeding episodes was small. Blood transfusions 
were required in 3.7% of the r&PA-treated patients and in 1.9% 
of the placebo-treated patients. On the basis of the available 
data it is impossible to establish the relative frequency of 
cerebral bleeding with streptokinase, APSAC or rt-PA because 
cerebrovascular accidents in large thrombolysis trials are most 
often reported as strokes and because computed tomography 
scans have not been performed systematically. 
B/ding cornplicutions after thrornbolyiic therupy possi- 
b/y corzsisr ofla,o grorrps (28): In the first group hemorrhagic 
complications are caused by the dissolution of a fibrin- 
stabilized hemostatic plug of a vascular lesion. The inci- 
dence of this type of bleeding is probably related to the 
efficacy of the thrombolytic agent. In the other group bleed- 
ing might be due to impaired primary hemostasis. In these 
patients the incidence of bleeding complications will be 
refated to the degree of systemic librinolytic activation and 
will be influenced by adjunctive antithrombotic and antiplate- 
let treatment. The most severe bleeding complications are 
expected to occur when the life-saving hemostatic plug of a 
vascular lesion is dissolved in the setting of a defective 
hemostasis due to severe hypolibrinogenemia. In view of 
these considerations, a careful evaluation not only of the 
incidence but also of the severity of the bleedin compttca- 
tions after different thrombolytic treatment regimens seems 
to be warranted. 
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Conclusions. The European Cooperative Study Group 
has clearly shown that the intravenous mfuslon of IT-PA after 
an acute myocardial infarction in addition to hepann a Id 
aspirin exerts a beneficial effect or. infarc! sire, left vcntzc 
ular function, early survival and cardiovascular morbidity, 
but at the cost of an increased risk of blecdmg. The &served 
beneficial effects indicate a substantial salvage of ischenic 
_..__^_ $..- A..- I.. .L. . ...-..,,, ,rrpcar ,u,t, uub w U,L cat,, admini;::~tioc of I?P.4 I-~-at- 
men: *with ti.-PA can there%re be recommended in patient5 
with acute myocardial infarction. Most ilk+. such treat- 
ment wili be cosi-elective (29). However, definite choice 
between the newer thrombolytic agents must await the 
results of ongoing (GISSI-2 and the International r&PA/ 
streptokinase mortality trial) and future (ISIS-3 trial) multi- 
center trials directly comparing the relative efficacy. safety 
and clinical benefit (including survival) of these drugs. 
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